Concepedia

Talimogene laherparepvec (T-VEC) in combination (combo) with ipilimumab (ipi) versus ipi alone for advanced melanoma: 3-year landmark analysis of a randomized, open-label, phase II trial

Jason Chesney, Igor Puzanov, Frances A. Collichio, Pallavi Singh, Mohammed Milhem, John A. Glaspy, Omid Hamid, Merrick I. Ross, Philip Friedlander, Claus Garbe,

Annals of Oncology · 2019 · 10 citations · 0 references

Open access

Concepts

MedicineOncologyPharmacotherapyCancer PharmacologyImmunotherapyTumor ImmunologyCancer ImmunotherapyCheckpoint Inhibitor TherapyCombination ImmunotherapyImmune Checkpoint InhibitorsImmunotherapy For Skin CancerMelanoma PharmacotherapyImmune Checkpoint Combination TherapyImmunotherapy For Skin TumorsMelanoma ImmunotherapyMelanoma ProgressionMetastatic Melanoma TreatmentPhase Ii InvestigationTalimogene Laherparepvec